For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Tinea infections are fungal infections caused by T rubrum, Trichophyton mentagrophytes and Epidermophyton floccosum. This dermatophyte fungus thrives in humid conditions. The clinical features of tinea pedis include patchy and dry scaling on foot and presence of blisters or pustules on feet and between toes.
Scope of the Report:
This report focuses on the Tinea Pedis Treatment in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The rising prevalence of diabetes that is fueling the incidence of tinea pedis is one of the primary growth factors for this market. There is an increased prevalence of diabetes across the globe due to high levels of sugar in the blood streams and this results in numerous health issues. Diabetes reduces the quality of life, increases the risk of obesity, and early death. People with diabetes tend to be more resistant to antifungal treatment regimens due to high blood glucose levels which increases the chances of fungal growth. Consequently, diabetes patients tend to have a high risk of foot ulcerations and infections that can lead to tinea pedis or onychomycosis resulting in the need for the effective treatment of this infection.
North America is the largest and reflects a high market attractiveness index. APEJ is the second largest regional market for tinea pedis treatment in terms of valuation and is the fastest growing region with a high CAGR of 6.1% recorded during the period of forecast.
The worldwide market for Tinea Pedis Treatment is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
- Exeltis USA
- Hisamitsu Pharmaceutical
- F. Hoffmann-La Roche
- Teva Pharmaceutical
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Market Segment by Applications, can be divided into
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
There are 15 Chapters to deeply display the global Tinea Pedis Treatment market.
Chapter 1, to describe Tinea Pedis Treatment Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Tinea Pedis Treatment, with sales, revenue, and price of Tinea Pedis Treatment, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Tinea Pedis Treatment, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Tinea Pedis Treatment market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Tinea Pedis Treatment sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source